The global acute coronary syndrome market is categorized based on various antihypertensive, antithrombotic and statins drugs.Based on evidence of heart muscle damage, the acute coronary syndrome is divided into three main types: unstable angina (UA), ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NSTEMI). UA occurs when heart doesn’t get enough blood flow and oxygen which leads to heart attacks. STEMI occurs when the coronary artery is completely blocked off by the blood clot. NSTEMI occurs when a coronary artery suddenly becomes partly occluded by blood clot.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3746
In terms of geographic, North America and Europe dominates the global acute coronary syndrome market. This is due to increased awareness about acute coronary syndrome in these regions. The U.S. represents the largest market for acute coronary syndrome market followed by Canada in North America. In Europe, Germany, Italy, the U.K. and France holds major share of acute coronary syndrome market. However, Asia is expected to show high growth rates in the next five years in global acute coronary syndrome market. This is due to many companies constructing their manufacturing facilities in the region. In addition, increasing awareness about acute coronary syndrome is also supporting in the growth of the market in the region. Japan, China and India are expected to be the fastest growing acute coronary syndrome markets in Asia.
In recent time, increasing aging population is key driver of the global acute coronary syndrome market. Increased pharmaceutical R&D investment and introduction of innovative drugs have fueled the growth of global acute coronary syndrome market. Extensive pipeline drugs with properties, such as high patient compliance and improved safety, are also supporting in the growth of global acute coronary syndrome market.
Increasing prevalence of diabetes and rising number of obese or over-weight people holds immense potential to the growth of global acute coronary syndrome market.
However, stringent regulations hamper the growth of global acute coronary syndrome market. Moreover, less number of approved drugs for the treatment of acute coronary syndrome also obstructs the growth of the market. Increasing mergers and acquisitions between drug manufacturing companies and rapid number of product launches are some of the major trends of the global acute coronary syndrome market.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/3746
Some of the major companies operating in the global acute coronary syndrome market are Boehringer Ingelheim, Dr. Reddy’s Laboratories, Johnson & Johnson, Teva Pharmaceuticals, Portola Pharmaceuticals, AbbVie, AstraZeneca, Amgen, Bayer, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Sanofi, Regeneron, Novartis and Merck.
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.
Persistence Market Research
7th Floor, New York City,
NY 10007, United States,
USA – Canada Toll Free: 800-961-0353